Understanding the Muscle Loss Challenge

GLP-1 receptor agonists have revolutionised weight management and metabolic health. Medications like semaglutide and tirzepatide are helping millions of people achieve meaningful weight loss and improve their cardiometabolic health. However, emerging research has uncovered a significant challenge: these powerful medications can lead to substantial losses in lean muscle mass alongside fat loss.

Pooled across 20 randomised controlled trials and 15,782 participants, 35.2% of the weight lost on semaglutide was lean mass rather than fat (Eisa N et al, Diabetes, Obesity and Metabolism 2026). Losing the same weight by diet alone cost 26.2% as lean mass in the same analysis, and the difference between the medications and lifestyle was not statistically significant (p = 0.42). The muscle comes off because the weight comes off, not because of the injection. Adding resistance training brought the share down to 17.5%, the most favourable result of any approach studied. For many patients this still matters a great deal, because muscle loss accelerates ageing, reduces metabolic rate, increases injury risk, and diminishes overall quality of life. Understanding the science behind it is essential for anyone on GLP-1 therapy who wants to preserve their muscle and maximise long-term health outcomes.

What the Major Clinical Trials Revealed

The largest and most rigorous clinical studies examining GLP-1 medications have provided sobering insights into lean mass changes. Let's examine the evidence:

"The STEP 1 trial showed that lean body mass comprises a meaningful proportion of total weight loss, with important implications for long-term metabolic health and physical function."
Published findings, 2021

These trials reveal a consistent pattern: wherever weight comes off, a substantial share of it is lean mass unless people specifically intervene with resistance training and adequate protein intake.

Semaglutide vs. Tirzepatide: Differences in Muscle Impact

Both semaglutide and tirzepatide are GLP-1 receptor agonists, but tirzepatide adds a secondary mechanism, it's also a GIP receptor agonist. What that means for any one person is a question for their prescriber. The question we can answer is whether it affects muscle differently.

Pooled across the 2026 meta-analysis the two shares were not identical: 35.2% for semaglutide and 25.4% for tirzepatide. Both drive weight loss through appetite suppression and metabolic changes, and both require the same interventions to preserve muscle. Whatever the medication, a larger total loss means a larger absolute calorie deficit, and that is what intensifies the pressure on muscle if it is not met with proper nutrition and training.

The bottom line: The medication class itself isn't the primary driver of muscle loss, it's the underlying metabolic changes and behavioural patterns that require management.

The Caloric Deficit: The Real Culprit

At its core, the muscle loss problem stems from the profound caloric deficit GLP-1 medications create. These drugs suppress appetite and increase satiety, making it easier to consume significantly fewer calories, often 500-1000+ calories per day less than baseline.

When the body enters a large caloric deficit, it must break down tissue to meet its energy needs. Without specific interventions, the body preferentially preserves fat (for evolutionary reasons) and sacrifices muscle tissue. This is particularly true when:

• Caloric deficit exceeds 500-750 kcal/day (the body triggers protein breakdown)
• Protein intake is insufficient to support muscle protein synthesis
• No resistance training stimulus signals the body to retain muscle
• Deficit persists for extended periods (weeks to months)

"The human body views muscle as metabolically expensive and will shed it during energy scarcity unless specific signals, mechanical tension from resistance training and amino acid availability from protein, convince it otherwise."
Nutrition physiology research, 2023

Protein Intake: The Game-Changer

One of the most actionable findings from recent research is the powerful role of protein intake in preserving lean mass during GLP-1 therapy.

For a 200-pound person, this means the difference between consuming 73 grams of protein daily (RDA) versus 120-175 grams (evidence-based for GLP-1 users). This isn't about extreme measures, it's consistent, deliberate protein consumption across meals and snacks.

The mechanism is simple: amino acids stimulate muscle protein synthesis. When adequate amino acids are available and the body receives resistance training stimulus, the brain signals muscles to preserve or even build tissue despite the caloric deficit. Without sufficient protein, this protective signal never arrives.

The Role of Resistance Training

Protein intake sets the foundation, but resistance training provides the signal. Mechanical tension during strength training activates muscle protein synthesis pathways and sends a clear biological message: "Keep this tissue; it's valuable."

Research on GLP-1 users who incorporated resistance training shows:

• Patients performing 2-3 strength sessions weekly preserved 35-50% more lean mass than non-training controls
• Progressive resistance (gradually increasing weight/difficulty) was more effective than static exercise
• Even moderate-intensity training (relative to individual capacity) significantly blunted lean mass loss
• The combination of adequate protein + resistance training nearly eliminated excess lean mass loss in some studies

The clinical trials rarely emphasised resistance training as a standard intervention, which partly explains the high lean mass losses observed. When resistance training is added to the protocol alongside adequate protein, outcomes improve dramatically.

What Researchers Are Recommending Now

Leading obesity researchers and sports medicine experts now advocate for a proactive, evidence-based approach to GLP-1 therapy:

• Protein intake of 1.2-1.6 g/kg body weight daily, distributed across meals to optimise muscle protein synthesis
• 2-3 resistance training sessions per week, targeting major muscle groups with progressive overload
• Adequate hydration and micronutrient intake to support metabolic health and training recovery
• Moderate caloric deficit (not excessive), aim for 0.25-0.5 kg weight loss weekly rather than rapid loss
• Regular monitoring of body composition (DEXA scans, bioelectrical impedance) to track lean mass preservation
• Professional guidance from registered dietitians and strength coaches familiar with GLP-1 populations

"The era of passive weight loss is over. Evidence now clearly supports active interventions combining adequate protein, resistance training, and moderate deficit management as standard care for GLP-1 users."
Contemporary obesity medicine guidelines, 2025

How EverStrong Applies This Research

Understanding the science is one thing; applying it consistently is another. This is where automated nutrition coaching becomes invaluable.

EverStrong is built on these exact research findings. Our platform:

• Calculates personalised protein targets based on your body weight, activity level, and GLP-1 medication type
• Provides daily coaching to help you hit protein goals through real food, not just supplements
• Integrates with fitness tracking to optimise nutrition around your resistance training sessions
• Monitors body composition trends and adjusts recommendations as your situation evolves
• Offers evidence-based meal planning that works with GLP-1's effects on appetite and eating capacity
• Connects you with expert support when questions arise about your specific situation

The research is clear. The path forward is clear. What's needed is consistency, guidance, and support, especially during the early months when your body is adapting to GLP-1 therapy.

The Bottom Line

Muscle loss on GLP-1 is not inevitable. It's a consequence of large caloric deficits without specific protective interventions. By combining adequate protein intake, consistent resistance training, and evidence-based coaching, you can preserve your muscle mass while achieving meaningful weight loss.

The clinical trials showed what happens without intervention. The emerging research now shows what's possible with intervention. Your role is to choose the path backed by evidence, and to get the support you need to stay on it.

Your muscle is your metabolic engine, your strength foundation, and your defence against ageing. Protecting it during GLP-1 therapy isn't vanity, it's health science.